Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Invested Capital: 2009-2025

Historic Invested Capital for Ani Pharmaceuticals (ANIP) over the last 15 years, with Sep 2025 value amounting to $822.7 million.

  • Ani Pharmaceuticals' Invested Capital fell 1.58% to $822.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $822.7 million, marking a year-over-year decrease of 1.58%. This contributed to the annual value of $726.6 million for FY2024, which is 10.08% down from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Invested Capital stood at $822.7 million, which was up 8.87% from $755.7 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Invested Capital high stood at $835.9 million for Q3 2024, and its period low was $300.6 million during Q3 2021.
  • In the last 3 years, Ani Pharmaceuticals' Invested Capital had a median value of $745.2 million in 2024 and averaged $749.8 million.
  • Its Invested Capital has fluctuated over the past 5 years, first spiked by 131.95% in 2022, then decreased by 10.08% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Invested Capital (Quarterly) stood at $687.8 million in 2021, then increased by 1.90% to $700.9 million in 2022, then rose by 15.29% to $808.1 million in 2023, then fell by 10.08% to $726.6 million in 2024, then declined by 1.58% to $822.7 million in 2025.
  • Its Invested Capital was $822.7 million in Q3 2025, compared to $755.7 million in Q2 2025 and $739.6 million in Q1 2025.